[
    {
        "file_name": "SUCAMPOPHARMACEUTICALS,INC_11_04_2015-EX-10.2-STRATEGIC ALLIANCE AGREEMENT.txt",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "For the purpose of creating a combined company that can drive considerable growth in global markets, including Japan, the Parties agree to form a strategic business alliance (the \"Strategic Business Alliance\") among Acquiror and SPI and its Affiliates (collectively, the \"Sucampo Group\") and the Company, subject to the successful Closing. The Parties intend to achieve the purpose of such Strategic Business Alliance by mutual cooperation in, among others, the following areas: (a) ensuring that the transaction contemplated in this Agreement would provide Sucampo Group with increased revenues—primarily from combining Sucampo Group's existing sales with those from the Company—enhanced profitability, strong cash flow generation and a robust balance sheet and the improved financial strength of SPI as the parent company would also accrue to the benefit of its subsidiaries, which will include the Company after the Closing; (b) ensuring that Sucampo Group and the Company together would have a deeper and broader development pipeline of potential drug candidates in development across four major therapeutic areas—gastroenterology, ophthalmology, autoimmune, and inflammation—and greater resources, both financially and operationally, to maximize these opportunities, and consistent with the Target Company's business strategy, such development pipelines (some of these drug candidates) could be out-licensed to external firms to create even greater value; and\n\n8\n\n(c) ensuring that both Sucampo Group and the Company would have greater opportunity to conduct business development transactions, and through the relationships of the Company and increased presence in the Japanese market, Sucampo Group would gain greater access to the Japanese biotech community and Japan's well-regarded scientific institutions and researchers, and the Company would receive access to Sucampo Group's expertise in identifying, negotiating and managing key alliances.",
                "changed_text": "For the purpose of creating a combined company that can drive considerable growth in global markets, including Japan, the Parties agree to form a strategic partnership (the \"Strategic Business Alliance\") among Acquiror and SPI and its Affiliates (collectively, the \"Sucampo Group\") and the Company, subject to the successful Closing. The Parties intend to achieve the purpose of such Strategic Partnership by mutual cooperation in, among others, the following areas: (a) ensuring that the transaction contemplated in this Agreement would provide Sucampo Group with increased revenues—primarily from combining Sucampo Group's existing sales with those from the Company—enhanced profitability, strong cash flow generation and a robust balance sheet and the improved financial strength of SPI as the parent company would also accrue to the benefit of its subsidiaries, which will include the Company after the Closing; (b) ensuring that Sucampo Group and the Company together would have a deeper and broader development pipeline of potential drug candidates in development across four major therapeutic areas—gastroenterology, ophthalmology, autoimmune, and inflammation—and greater resources, both financially and operationally, to maximize these opportunities, and consistent with the Target Company's business strategy, such development pipelines (some of these drug candidates) could be out-licensed to external firms to create even greater value; and\n\n8\n\n(c) ensuring that both Sucampo Group and the Company would have greater opportunity to conduct business development transactions, and through the relationships of the Company and increased presence in the Japanese market, Sucampo Group would gain greater access to the Japanese biotech community and Japan's well-regarded scientific institutions and researchers, and the Company would receive access to Sucampo Group's expertise in identifying, negotiating and managing key alliances.",
                "explanation": "The term 'Strategic Business Alliance' is changed to 'Strategic Partnership' without any definition of 'partnership'. This can create uncertainty as the implications and legal obligations are different, making the agreement ambiguous.",
                "location": "Section 2.01"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "Each Party shall cooperate and use its reasonable efforts in making all notifications to, and seeking all consents of, Governmental Authorities necessary or advisable to consummate the transactions contemplated hereby as promptly as practicable. No Party shall take any action that would reasonably be expected to prevent or materially delay or impede the filing or receipt of such necessary or advisable notifications or consents.",
                "changed_text": "Each Party shall cooperate and use its commercially reasonable efforts in making all notifications to, and seeking all consents of, Regulatory Agencies necessary or advisable to consummate the transactions contemplated hereby as promptly as practicable. No Party shall take any action that would reasonably be expected to prevent or materially delay or impede the filing or receipt of such necessary or advisable notifications or consents.",
                "explanation": "Changing 'Governmental Authorities' to 'Regulatory Agencies' introduces a subtle but potentially significant difference.  While often used interchangeably, the precise scope and definition can vary, leading to confusion regarding which entities' consents are required.",
                "location": "Section 4.03"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "Following the Closing Date, SPI shall develop an integration plan in consultation with the management of the Company as required for combining the business operations of the two companies. Subject to the goals, parameters and integration activities outlined in the integration plan, SPI shall (i) provide the employees of the Company with employee incentives under such terms and conditions as not less favorable (taking into account, among other things, tax implications) to the incentives made available by the Company to such its employees as of the date of this Agreement […***…], and thereafter under such terms and conditions as not less favorable (taking into account, among other things, tax implications, local laws, and SPI's practices with respect to the employees of Acquiror) to those of the incentives made available by SPI to its employees, and (ii) […***…] the […***…] of the […***… ] of the […***…] as of the […***…] of this [… ***…] at […***…] the […***…] of the […***…] of the […***…] on […***…]. For the sake of achieving the purpose of the strategic alliance as set forth in Section 2.01, both Parties acknowledge their mutual intention to, in principle, maintain the Company's employment at levels consistent with the requirements of the Company from time to time.",
                "changed_text": "Following the Closing Date, SPI shall develop an integration strategy in consultation with the executives of the Company as required for combining the business operations of the two companies. Subject to the goals, parameters and integration activities outlined in the integration strategy, SPI shall (i) provide the workers of the Company with employee incentives under such terms and conditions as not less favorable (taking into account, among other things, tax implications) to the incentives made available by the Company to such its employees as of the date of this Agreement […***…], and thereafter under such terms and conditions as not less favorable (taking into account, among other things, tax implications, local laws, and SPI's practices with respect to the employees of Acquiror) to those of the incentives made available by SPI to its employees, and (ii) […***…] the […***…] of the […***… ] of the […***…] as of the […***…] of this [… ***…] at […***…] the […***…] of the […***…] of the […***…] on […***…]. For the sake of achieving the purpose of the strategic alliance as set forth in Section 2.01, both Parties acknowledge their mutual intention to, in principle, maintain the Company's employment at levels consistent with the requirements of the Company from time to time.",
                "explanation": "Changing 'integration plan' to 'integration strategy', 'management' to 'executives' and 'employees' to 'workers' without defining these differences causes confusion. It becomes unclear if 'executives' are a subset of 'management' or if 'workers' encompasses a different group than 'employees'. This affects the obligations under this section.",
                "location": "Section 4.10"
            }
        ]
    }
]